Crexendo and NUSO Partner to Deliver Global Cloud Communications Capabilities
23.10.2025 15:15:00 CEST | Business Wire | Press Release
NUSO, a leading provider of cloud communications service delivery, today announced it has been chosen by Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, to be a preferred carrier for the Crexendo cloud communications platform. The expanded partnership allows Crexendo platform licensees to offer cloud communications capabilities over NUSO’s global delivery network, unlocking new revenue opportunities for service providers. With NUSO’s carrier footprint in more than 40 countries, the Crexendo platform now offers global service delivery with industry-leading call quality, uptime, and emergency calling compliance. Platform providers can now offer global service delivery to over 6 million end users worldwide who rely on Crexendo’s Netsapiens platform.
"Crexendo has long been an award-winning, trusted cloud communications platform provider, and our partnership with NUSO further extends our platform’s features on a global scale,” said Jeff Korn, Crexendo Chairman and CEO. “We appreciate NUSO’s service expansion and increased investment in the NetSapiens Platform in the US and Europe. In addition, our platform licensees now have new opportunities to generate revenue by offering these new global capabilities to their end-user customers. I’m very excited about Crexendo’s partnership with NUSO, and their Event Sponsorship of our User Group Meeting in Miami Beach next week. This partnership is yet another example of the growth and advancements in our platform that we continue to make for our valued service providers and their customers.”
“Crexendo’s platform has long set the standard for innovation and partner enablement in cloud communications,” said Matt Siemens, CEO of NUSO. “We’re proud to extend that vision globally through our carrier network and platform capabilities. Together, we’re giving service providers the reach, reliability, and compliance they need to deliver world-class communications anywhere their customers do business.”
Additional information on the NUSO partnership will be shared at Crexendo’s upcoming NetSapiens Platform User Group Meeting (UGM) to be held in Miami Beach, Florida, from October 27 through October 30, where the industry's leading service providers and technology partners come together to shape the future of cloud communications. NUSO is an Event Sponsor of Crexendo’s 2025 UGM.
About NUSO
NUSO is a global cloud communications provider that brings together AI powered voice, messaging, collaboration, contact center, and carrier-grade infrastructure in one secure platform. NUSO helps partners and enterprises scale faster, meet compliance demands, and deliver better customer experiences. With NUSO, organizations move beyond call routing to orchestrating the outcomes that matter. NUSO is ISO 27001:2022 certified and operates across the United States, Canada, Latin America, UK, and EMEA. Learn more at www.nuso.cloud.
About Crexendo
Crexendo, Inc. is an award-winning software technology company that is a premier provider of cloud communication platform and services, video collaboration and managed IT services tailored to businesses of all sizes. Our solutions currently support over six million end users globally, through our extensive global network of over 235 cloud communication platform software subscribers and our direct retail offering. For more information, please visit www.crexendo.com.
Safe Harbor Statement
This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor'' for such forward-looking statements. The words, "believe,'' "expect,'' "anticipate,'' "estimate," "will'' and other similar statements of expectation identify forward-looking statements. Specific forward-looking statements in this press release include information about Crexendo (i) allowing platform licensees to offer cloud communications capabilities over NUSO’s global delivery network; (ii) unlocking new revenue opportunities for service providers; (iii) platform offering global service delivery with industry-leading call quality, uptime, and emergency calling compliance; (iv) platform providers offering global service delivery to over 6 million end users worldwide who rely on Crexendo’s platform; (v) partnership with NUSO further extending its platform’s features on a global scale; (vi) platform licensees having new opportunities to generate revenue by offering these new global capabilities to their end-user customers; (vii) partnership being yet another example of the advancements in our platform we continue to make for our valued service providers and their customers; (viii) setting the standard for innovation and partner enablement in cloud communications; (ix) extending that vision globally through NUSO’s carrier network and platform capabilities; (x) giving service providers the reach, reliability, and compliance they need to deliver world-class communications anywhere their customers do business; (xi) sharing information on the NUSO partnership at Crexendo’s upcoming NetSapiens Platform User Group Meeting (UGM).
For a more detailed discussion of risk factors that may affect Crexendo's operations and results, please refer to the company's Form 10-K for the year ended December 31, 2024, and Form 10-Qs as filed with the SEC. These forward-looking statements speak only as of the date on which such statements are made, and the company undertakes no obligation to update such forward-looking statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251023910688/en/
Contacts
NUSO Contact:
Colleen Sheley
VP of Marketing, NUSO
marketing@nuso.cloud
Crexendo Contact:
Doug Gaylor
President and Chief Operating Officer
dgaylor@crexendo.com
602-732-7990
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom